Patent Due Diligence for Investors
Overview
Patent Due Diligence for Investors
Before an equity investment, the investor wants to be sure of three things: does the technology really belong to the company, can it be effectively protected, and is it clear of third-party rights (freedom to operate). That is what patent due diligence – the investor’s IP review – is for: it covers the company’s entire intellectual property, not just a single patent.
At EUPATENT, we support startups, VC funds and investors in assessing rights to inventions, patent applications, code, know-how, trademarks, designs and agreements with creators. We help you put the IP in order before the funding round – to reduce risk and strengthen the company’s negotiating position.
Why do investors check patents before deciding?
A patent or a patent application genuinely influences the investment decision – but only if it is well prepared and actually protects a solution that matters to the business. The data backs this up: startups granted their first patent are about 53% more likely to raise VC funding, and over the following five years they record markedly higher employment and sales growth (Farre-Mensa, Hegde and Ljungqvist, Journal of Finance, 2020).
For an investor, IP is rarely priority number one – it usually ranks behind market and team. But it acts as a gate: in industries where protection is critical (deep tech, biotech, hardware), its absence can kill the deal. The weight of IP grows as the company matures and peaks at exit.
Interested in working with us? Get in touch.
The IP due diligence process step by step
Investors usually examine IP in three stages. It helps to know what to expect at each of them:
- Initial screening. The investor assumes the IP is “fine” and focuses on the market, the product and the team. At this stage, the founders’ very willingness to invest in IP is already a positive signal.
- Deep-dive analysis. The investor verifies the actual state of play: who owns the rights, how broad the claims are, whether there is a risk of infringing third-party rights (FTO) and whether protection can be extended to the target markets.
- Formal due diligence (after the term sheet). A full review of the documentation in the data room: agreements with creators and contractors, filing history, status of proceedings, licenses, trademarks and open-source dependencies.
The audit typically covers patent documentation, agreements with creators, filing history, R&D results, code repositories, licenses, trademarks and potential infringements. The scope and validity of the claims are checked too, along with the options for extending protection abroad.
The most common red flags in patent due diligence
The most common problems that surface during due diligence:
- Rights never transferred from the creators. The most dangerous mistake. If the investor discovers that part of the code or the invention legally belongs to B2B contractors or a software house, the deal can simply collapse.
- Disclosure of the invention before filing. Europe applies absolute novelty – unlike the US, there is no one-year grace period for your own disclosures. A launch, a demo, a scientific publication or a trade fair before filing usually closes the door to a patent at the EPO and in Poland for good (Art. 54–55 EPC, Art. 25(5) of the Polish Industrial Property Law; a narrow 6-month exception covers only evident abuse and selected exhibitions). Note: a launch in Poland counts as disclosure across the entire EU.
- Claims that are too narrow or poorly drafted. A patent that is easy to design around or whose infringement cannot be detected provides only illusory protection.
- No territorial strategy. Protection in a single country despite global commercialization plans.
- Conflict with a third-party patent (no FTO). The risk that the product encroaches on someone else’s earlier patent.
- Unclear rights to code written by a software house or a freelancer.
Contact
Let's talk about protecting your brand
Tell us where you want to protect your name or logo. We'll prepare an action plan and a quote.
How do you prepare a startup for a VC fund’s IP review?
A well-prepared company can show the investor three things: what it owns, how it protects it, and which risks it has already analyzed. In practice, it pays to:
- put agreements with creators, employees and contractors in order (a complete chain of rights transfers),
- gather the technical documentation, the development history of the solution, filings, licenses and technology usage policies,
- prepare a concise “IP one-pager” and a data room before the fund asks for one,
- audit your open-source dependencies for compatibility with your commercialization model.
IP awareness on the founders’ side is itself a separate, positive signal for the investor.
Patent due diligence and company valuation
IP is rarely a separate line item in the valuation of an early-stage startup. It works indirectly: it reduces the investor’s risk and lifts the valuation multiple of the whole company – it makes the technology harder to copy, supports licensing, secures the market and strengthens negotiations with partners.
The mere news of a patent application is not enough. What counts is the scope of protection, the quality of the documentation, how detectable infringements are, and whether the patent really protects a solution that matters to the business model. A patent that cannot be enforced is often a cost, not an asset.
An IP audit before the funding round – invest in peace of mind
An IP audit uncovers problems before the investor does. That gives you time to fix agreements, complete the documentation, broaden protection or prepare your case for talks with the fund. This matters most in technology companies whose business value rests on intellectual property – and where a single due diligence finding can drag down the entire valuation.
Planning a funding round or an exit? Book an IP audit with EUPATENT – we will check your patent and your entire portfolio before the investor does.
FAQ
Frequently asked questions
IP due diligence is the investor's "X-ray" of a company's intellectual property: who really owns the technology, whether the patents are valid, and whether the company infringes third-party rights. It is usually part of a broader company review – in VC rounds the whole process typically takes 2 to 6 weeks (less for a seed round, longer for larger rounds), with the IP workstream itself taking a few days to two weeks. In acquisitions and in heavily patent-driven industries (biotech, medtech) it can take much longer. Well-organized documents can shorten this time considerably.
Often yes – especially at an early stage. A pending application secures the priority date and is a positive signal in itself; research shows that startups with patents grow faster and raise funding more easily. The investor, however, looks not only at whether an application exists, but at whether the scope of protection actually covers what gives the company its market edge. The founders' IP awareness (filing strategy, transfer of rights) can matter as much as the document itself. In industries such as biotech, "patent pending" alone may not be enough.
The investor reconstructs the chain of title – checking that all rights to the technology actually belong to the company. They ask about agreements with founders, employees and B2B contractors, and whether those agreements transfer copyright in the code and the rights to inventions to the company. They also review open-source licenses and any university contribution. The most common problem is developers on B2B contracts without an effective transfer of rights – if part of the code turns out to belong to them legally, the deal can fall apart. That is why these agreements are worth sorting out in advance.
That risk is examined in a freedom-to-operate (FTO) analysis – whether you can sell your product without running into third-party patents that are in force. If the analysis finds a conflict, there are usually three ways out: design around the patent by changing the solution, buy a license, or challenge the patent's validity. Investors do not expect a full FTO analysis before they invest, but they want to see that the company is aware of the risk and is not ignoring the competition. An undetected conflict can torpedo both the funding round and the business itself.
Yes. Patents are territorial – they protect only in the countries where they were granted, so a Poland-only patent is weak if your market is the whole world. An investor aiming for global growth expects protection in the key markets (most often the US and Europe). In practice, this is arranged through a priority filing followed by the international PCT procedure, which buys time to choose the countries. For Polish startups, thinking "global from day one" therefore applies to patent strategy too, not just to sales.
The most common: claims that are too narrow and easy to design around; a broken chain of title (e.g. contractors' code without a transfer of rights); and claims whose infringement cannot be detected – such as an algorithm running "inside" a competitor's server. Another red flag is public disclosure of the invention (a conference, a publication) before filing, because it destroys novelty and can kill the patent in Europe. It does happen that an investor walks away after a patent is heavily narrowed during examination and loses its business value.
Yes, in several ways. Before the review, a patent attorney runs an IP audit – putting rights transfers, open-source licenses and the filing portfolio in order so that the investor finds no gaps to push the valuation down. They can also translate patents into business language: showing what they really protect and how they block competitors, which strengthens the founders' position at the negotiating table. During the deal, they often join the team alongside the M&A advisor and the lawyer. The earlier they come on board, the fewer "surprises" turn up at the worst possible moment.
Investors do not value a patent as a trophy; they value a right that can be enforced. Two conditions are key. First, detectability: you must be able to prove that a competitor is using your invention – a patent on an algorithm hidden in someone else's server is practically worthless. Second, the right target: the claim should catch your competitor, not your own customer. Beyond that, the patent should protect what customers actually pay for (the market advantage), not just a clever technical trick.
Sometimes yes – it is a genuine alternative, not a lesser choice. A trade secret better protects solutions that are hard to spot in the product itself (e.g. formulations, process parameters, training data for AI models), because it requires no disclosure and can last for years. A patent is better when infringement can be detected and when you plan licensing or a sale of the company – it is a measurable asset, easier to value in investor due diligence. A trade secret "costs" discipline: NDAs, access control, procedures. In practice, the best strategies combine both: patents for some elements, secrecy for others.